Biotek-snakken — Maj 2021
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Orphazyme A/S - ORPH
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Orphazyme A/S ("Orphazyme" or the "Company") (NASDAQ: ORPH). Such investors are...
(www.prnewswire.com)
-
-
Til gengæld er jeg lidt træt af partial clinical hold på MYOV (som jeg fik fisket af i dybet) - ser ud til at vi skal en tur ned igen
https://www.marketwatch.com/story/myovants-stock-falls-after-fda-puts-partial-clinical-hold-on-trial-for-contraceptive-candidate-2021-05-19?siteid=yhoof2 -
Det bliver også spændende, når embargo løftes for Sutros STRO-002 abstract. For de interesserede kan det findes her: https://meetinglibrary.asco.org/results/Sutro Biopharma . Data bliver tilgængelige kl. 23 aften, så vidt jeg kan finde frem til
-
Sutros ny STRO-002 data er opsummeret i denne opdaterede corporate presentation: https://www.sutrobio.com/corporate-presentation/
-
Egentlig synes jeg, at det ser fornuftigt ud. Desværre ingen nye responses blandt de tilbageværende, men samlet mPFS på 7.2 måneder - til sammenligning havde ImmunoGen 4.8 måneder i deres P3 forsøg i langt mindre behandlede patienter. https://investor.immunogen.com/news-releases/news-release-details/immunogen-presents-full-data-phase-3-forward-i-study
-
Derudover flere datapunkter på FolRa udtryk - jeg noterer mig, at STRO-002 ser ud til at have virkning i low og intermediate patienter. Til sammenligning viser Mirvetuximab stort set kun effekt i FolRa high
-
Er svagheden i biotekaktier forbigående? Bryder Novo Nordisk ud af sit kursinterval? Er inflationsfaren reel – eller er det et buzzword? Samt verden ifølge elonmusk
& tsla. Lyt med i afsnit 66 af Investeringspodcasten med PerNordnet
ogHelgeLarsen. https://www.nordnet.dk/blog/afsnit-66-af-investeringspodcasten-om-biotekaktier-og-verden-ifoelge-elon-musk/ -
Cantargia: Cantargia reports positive results in ongoing phase IIa clinical trial in pancreatic cancer using nadunolimab and chemotherapy.https://cantargia.com/en/press-releases/cantargia-reports-positive-results-in-ongoing-phase-iia-clinical-trial-in-pancreatic-cancer-using-nadunolimab-and-chemotherapy
-
2cureX's clinical partner, University Hospital Vejle, presents positive results of the
IndiTreat
-guided clinical trial in third line metastatic colorectal cancer at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting: https://www.proinvestor.com/index.php?p=debat_1&postid=93670 -
Cantargia, Capital Markets Day, 2021
May 20th 2021 15:00 (Europe/Stockholm)
Language:
English
Speaker:
CEO, Göran Forsberg. VP Research, David Liberg. CMO, Ignacio Garcia-Ribas. Ahmad Awada, Professor at Institut Jules Bordet and Manuel Hidalgo Medina, M.D. Ph.D. Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine.
Sector:
Health care - Pharmaceuticals & Biotechnology
Listing:
Mid Cap
Activity:
Capital Markets DayTilmelding:
Eks. har Chiasma 6-7 af de der standard-søgsmål i forbindelse med sammenlægning med AMYT, og jeg ser det på en række af de US biotek jeg følger 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind